Cargando…

Wegener's granulomatosis: current and upcoming therapies

Wegener's granulomatosis is a complex multisystem disease that can be associated with morbidity and mortality. The introduction of cyclophosphamide and glucocorticoids brought about the potential for long-term survival and provided the opportunity and impetus to explore treatment options that c...

Descripción completa

Detalles Bibliográficos
Autor principal: Langford, Carol A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165064/
https://www.ncbi.nlm.nih.gov/pubmed/12823849
http://dx.doi.org/10.1186/ar771
_version_ 1782120829380722688
author Langford, Carol A
author_facet Langford, Carol A
author_sort Langford, Carol A
collection PubMed
description Wegener's granulomatosis is a complex multisystem disease that can be associated with morbidity and mortality. The introduction of cyclophosphamide and glucocorticoids brought about the potential for long-term survival and provided the opportunity and impetus to explore treatment options that can reduce the toxicity of therapy and lessen the likelihood of relapse. With the growth of knowledge regarding disease pathophysiology and the increasing ability to selectively target the immune system, the potential options for therapeutic investigation have continued to expand. Careful study of new agents through rigorously designed trials is essential to answering questions of safety and efficacy in Wegener's granulomatosis.
format Text
id pubmed-165064
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1650642003-07-12 Wegener's granulomatosis: current and upcoming therapies Langford, Carol A Arthritis Res Ther Review Wegener's granulomatosis is a complex multisystem disease that can be associated with morbidity and mortality. The introduction of cyclophosphamide and glucocorticoids brought about the potential for long-term survival and provided the opportunity and impetus to explore treatment options that can reduce the toxicity of therapy and lessen the likelihood of relapse. With the growth of knowledge regarding disease pathophysiology and the increasing ability to selectively target the immune system, the potential options for therapeutic investigation have continued to expand. Careful study of new agents through rigorously designed trials is essential to answering questions of safety and efficacy in Wegener's granulomatosis. BioMed Central 2003 2003-05-29 /pmc/articles/PMC165064/ /pubmed/12823849 http://dx.doi.org/10.1186/ar771 Text en
spellingShingle Review
Langford, Carol A
Wegener's granulomatosis: current and upcoming therapies
title Wegener's granulomatosis: current and upcoming therapies
title_full Wegener's granulomatosis: current and upcoming therapies
title_fullStr Wegener's granulomatosis: current and upcoming therapies
title_full_unstemmed Wegener's granulomatosis: current and upcoming therapies
title_short Wegener's granulomatosis: current and upcoming therapies
title_sort wegener's granulomatosis: current and upcoming therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165064/
https://www.ncbi.nlm.nih.gov/pubmed/12823849
http://dx.doi.org/10.1186/ar771
work_keys_str_mv AT langfordcarola wegenersgranulomatosiscurrentandupcomingtherapies